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3963 1942 1917 574 212 
Data collection 
period 
From 1998  From 1998 2007 to 2017 2011 to 2013 2013 to 2015 
 
Study design Longitudinal Longitudinal Cross sectional Longitudinal Cross sectional 
Setting Primary and 
secondary care  in 
Tayside, Scotland 
Primary and secondary 
care in West-Friesland, 
Netherlands 
Primary and secondary 
care in eight diabetes 
research regions, 
England and retinal 
screening clinics. 
 
Primary and secondary 
care in South West 
England 
Primary and secondary 
care in Exeter, Dundee 
and Oxford, England 
Inclusion criteria Clinical diagnosis of 
type 2 diabetes. 
Clinical diagnosis of type 
2 diabetes. 
Clinical diagnosis of 
diabetes (any type). 
Clinical diagnosis of 
type 2 diabetes. 
Clinician determined 
requirement for DPP-IV 




Clinical diagnosis of 
type 2 diabetes non-
insulin treated within 6 
months of diagnosis. 
Participants were 
selected on the basis of 
rapid or slow 
progression to insulin 
therapy (<7, >7 years).  
Age 18-90 inclusive.  
 
Data collection Clinical measurements 
and blood collected at 
initial visit. Follow up 





collected at initial visit, 
and repeated annually. 
Blood collected at one of 
the annual visits. 
Additional health data 
collected using electronic 
medical record linkage. 
Clinical measurements 
and blood sample 
collected at visit. 
Ongoing biochemical 
data collected from 
pathology laboratories. 
Clinical measurements 
and blood taken at 
initial visit. Follow up 
clinical measurements 
and blood collected at 
three and six months. 
Clinical measures and 
fasting blood sample 
taken at visit. 














Supplementary Figure { SEQ Supplementary_Figure \* ARABIC }: Participant flow diagram * identified through search of electronic laboratory records. 
Missing data/excluded participants (n = 1334) 
 Non-white European ethnicity: 97 
 Time to insulin or duration not available: 467 
GADA not available: 53 
 Failed genotyping: 670 
 Clinical GADA testing*: 47  
Insulin treated (n = 1816) Non-insulin treated (n = 6792) 
Exeter DARE eligible 
participants (n = 2964) 
 
DCS eligible participants 
(n = 2010) 
 
GoDarts eligible 
participants (n = 3994) 
 
PRIBA eligible participants  
(n = 718) 
 
MRC Progressor eligible 
participants (n = 256) 
 





MRC Progressor: 212 
 
SNP Gene Odds Ratio Weight 
 Effect Allele 
rs2187668, 
rs7454108 
DR3/DR4 48.18 3.87  
 
DR3/DR3 21.12 3.05  
DR4/DR4 21.98 3.09  
DR4/X 7.03 1.95  
DR3/X 4.53 1.51  
rs1264813 HLA_A_24 1.54 0.43  T 
rs2395029 HLA_B_5701 2.5 0.92  T 
rs3129889 HLA_DRB1_15 14.88 2.70  A 
rs2476601 PTPN22 1.96 0.67  A 
rs689 INS 1.75 0.56  T 
rs12722495 IL2RA 1.58 0.46  T 
rs2292239 ERBB3 1.35 0.30  T 
rs10509540 C10orf59 1.33  0.29  T 
rs4948088 COBL 1.3 0.26  C 
rs7202877   1.28 0.25  G 
rs12708716 CLEC16A 1.23 0.21  A 
rs3087243 CTLA4 1.22 0.20  G 
rs1893217 PTPN2 1.2 0.18  G 
rs11594656 IL2RA 1.19 0.17  T 
rs3024505 IL10 1.19  0.17  G 
rs9388489 C6orf173 1.17  0.16  G 
rs1465788   1.16 0.15  C 
rs1990760 IFIH1 1.16 0.15  T 
rs3825932 CTSH 1.16 0.15  C 
rs425105   1.16 0.15  T 
rs763361 CD226 1.16 0.15  T 
rs4788084 IL27 1.16 0.15  C 
rs17574546   1.14 0.13  C 
rs11755527 BACH2 1.13 0.12  G 
rs3788013 UBASH3A 1.13 0.12  A 
rs2069762 IL2 1.12 0.11  A 
rs2281808   1.11 0.10  C 
rs5753037   1.1 0.10  T 
Supplementary Table 2: Type 1 diabetes SNPs included in the genetic risk score with weights. Effect 










SNP Gene Odds Ratio Weight 
 Effect Allele 
rs2187668, 
rs7454108 
DR3/DR4 48.18 3.87  
 
DR3/DR3 21.12 3.05  
DR4/DR4 21.98 3.09  
DR4/X 7.03 1.95  
DR3/X 4.53 1.51  
rs1264813 HLA_A_24 1.54 0.43  T 
rs2395029 HLA_B_5701 2.5 0.92  T 
rs3129889 HLA_DRB1_15 14.88 2.70  A 
rs2476601 PTPN22 1.96 0.67  A 
rs689 INS 1.75 0.56  T 
rs12722495 IL2RA 1.58 0.46  T 
rs2292239 ERBB3 1.35 0.30  T 
rs10509540 C10orf59 1.33  0.29  T 
Supplementary Table 3: Type 1 diabetes SNPs included in the 10 SNP T1D GRS 
 
  DCS Hoorn  
(n = 1 942) 
GoDarts 
 (n = 3 963) 
Exeter studies 
(n= 2 702 ) 
p-value 
Sex (% Male) 54.6% 54.8% 60.2% <0.001 
Age at diagnosis (years) 60 (53, 67) 61 (54, 68)  59 (50, 67) <0.001 
BMI (kg/m2)* 29.5 (26.8, 33.2) 30.4 (27.2, 34.6) 31.1 (27.5, 35.7) <0.001 
Duration of diabetes (years) † 7.1 (4.3, 11.0) 12.8 (10.3, 15.7) 7.0 (3.0, 12.3) <0.001 
Duration of diabetes (years) at GADA  8.2 (5.3, 12.2) 5.1 (2.7, 8.0) 7.0 (3.0, 12.0) <0.001 
Insulin treated within 5 years (%)‡ 5.8 7.4 10.2 <0.001 
HbA1c (%)† 6.5 (6.1, 7.1) 7.2 (6.5, 8.2) 7.3 (6.6, 8.4) <0.001 
HbA1c (mmol/mol) † 48 (43, 54) 55 (48, 66) 56 (49, 68) <0.001 
GADA Positive (%) 2.2% 3.9% 3.1% <0.001 
T1D GRS centile§ 4.7 (0.9, 16.1) 3.9 (0.5, 15.9) 4.2 (0.7, 16.3) <0.001 
     
Supplementary Table 4: Participant characteristics stratified by cohort. Median (IQR) or % 
Kruskal-Wallis used for comparison testing continuous variables, chi-square for categorical variables 
Exeter cohorts are shown combined due to low numbers in PRIBA and MRC Progressor  
* Closest to diagnosis 
† At latest follow up   
‡ Percentage of participants observed for at least five years 
§ Centile of participants with type 1 diabetes from the Wellcome trust case control consortium. 
 
  
Supplementary Figure 2: Kaplan-Meier plot of probability of requiring insulin therapy by risk group using 10 SNP T1D GRS. Solid lines represent GADA 
positive groups, dashed lines represent GADA negative groups. Blue = low T1D GRS centile, orange = medium T1D GRS centile, red = high T1D GRS 
centile. 
 High T1DGRS Ab+
 Med T1DGRS Ab+
 Low T1DGRS Ab+

































492 486 465 427 396 368High T1DGRS Ab -
3545 3501 3335 3084 2826 2601Med T1DGRS Ab -
4291 4247 4066 3765 3504 3238Low TIDGRS Ab -
51 49 43 34 28 25High T1DGRS Ab+
131 126 111 101 89 83Med T1DGRS Ab +
98 96 89 82 74 71Low TIDGRS Ab +
Number at risk
0 1 2 3 4 5
Time before insulin required (years)
Variable Hazard Ratio (95% CI) p value 
GADA Negative  1  
GADA Positive 3.70 (2.74, 4.99) <0.001 
GADA Negative:10 SNP T1D GRS (per 1 SD change in T1D GRS) 1.04 (0.96, 1.14) >0.1 
GADA Positive:10 SNP T1D GRS (per 1 SD change in T1D GRS) 1.34 (1.05, 1.71) 0.02 
Age at diagnosis (per 1 year) 0.97 (0.96, 0.98) <0.001 
BMI (per kg/m2 unit) 1.00 (0.98, 1.01) >0.1 
Supplementary Table 5: Hazard ratios from Cox proportional regression model for time to insulin censored at 5 years (10 SNP T1D GRS)  




Number at risk  
       
No Copies Ab+ 15 15 13 11 9 8 
One Copy Ab+ 27 25 22 20 17 16 
Two Copies Ab+ 69 67 59 50 45 40 
No Copies Ab- 10 10 9 7 5 3 
One Copy Ab- 42 40 36 33 31 30 
Two Copies Ab- 117 114 104 96 84 82 
       

































0 1 2 3 4 5
Time before insulin required (years)
DRStatusab =  DR3/DR3Ab+ DRStatusab = DR3/DR4Ab+ DRStatusab = DR3/XAb+
DRStatusab = DR4/DR4Ab+ DRStatusab = DR4/XAb+ DRStatusab = X/XAb+
DRStatusab = DR3/DR3Ab- DRStatusab = DR3/DR4Ab- DRStatusab = DR3/XAb-
DRStatusab = DR4/DR4Ab- DRStatusab = DR4/XAb- DRStatusab = X/XAb-
  
Supplementary Figure 4: Kaplan-Meier plot of probability of requiring insulin therapy by risk group using HLA DR3/DR4 alleles. Solid lines represent GADA 





































524 516 494 446 411 385Two Copies Ab -
3186 3152 3016 2791 2574 2365OneCopies Ab -
4617 4565 4355 4038 3740 3456NoCopies Ab -
52 50 44 38 31 27Two Copies Ab+
111 107 95 83 76 70OneCopy Ab +
117 114 104 96 84 82NoCopies Ab+
Number at risk
0 1 2 3 4 5
Time before insulin required (years)
